Roche Reports Long-Term Data for Rozlytrek in ROS1-Positive NSCLC and NTRK Fusion Cancers

Roche today presented long-term follow-up data for Rozlytrek (entrectinib) in patients with ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. The data showed that Rozlytrek maintained durable responses, with median duration of response of 20.5 months in ROS1-positive NSCLC and 24.6 months in NTRK fusion-positive tumors.